45 minutes
US financial regulations meant to limit access to military and other strategic technologies has inadvertently caught biotech in its wake, preventing investment from some of the largest global biotech investment sources including Chinese investment funds. Come hear legal, investor and company experts discuss what companies and co-investors need to know about CFIUS' impact on new and proposed investment rules.


Johnny Hu - Associate, Omega Funds
Linda Ji - Partner, McDermott Will & Emery LLP
Lisa Schaefer - Director of Financial Services & Tax Policy, BIO
Vikas Goyal - SVP Business Development, Pandion Therapeutics
Name Audience
Business Track